Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.30 |
| ▸ | SELP | P16109 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8340109 | 0.94 | ALDH1A1 (0.40) | PGK1PGK2ALDH1A1TSHRCYP11B1 | |
| SCHEMBL24709410 | 0.89 | PGK1 (0.37) | PGK1PGK2 | |
| SCHEMBL5442950 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL257934 | 0.82 | ACHE (0.36) | PGK1PGK2ACHEIDH1IDO1 | |
| SCHEMBL13177269 | 0.82 | RAPGEF4 (0.33) | PGK1PGK2TSHRIDO1 | |
| SCHEMBL28056120 | 0.82 | TACR1 (0.40) | PGK1PGK2ALDH1A1IDO1 | |
| SCHEMBL12833353 | 0.75 | PTGS2 (0.39) | TAAR1 | |
| SCHEMBL21306511 | 0.75 | PTGS2 (0.39) | TAAR1 | |
| SCHEMBL27057373 | 0.73 | RAPGEF4 (0.33) | — | |
| SCHEMBL5675646 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207915-A1 | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | USV LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007039913-A1 | PROCESS FOR THE PREPARATION OF 2,2’-[5-(1,2,4-TRIAZOLE-1-YLMETHYL) -1,3-PHENYLENE] DI (2-METHYLPROPIONITRILE). | USV LIMITED (IN) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207915-A1 | Process for the Preparation of 2,2'-[5-(1H-1,2,4-Triazole-1-Ylmethyl) -1,3-Phenylene] Di (2-Methylpropionitrile) | CYP19A1, CYP11A1, HCN2 | PGK1 3598/4885PGK2 3262/4885ALDH1A1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.